

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: December 9, 2008 Signature: Jeanne M. Brashear/56,301
(Jeanne M. Brashear)

Docket No.: 28967/34891.1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kari Alitalo et al.

Application No.: 10/774,802

Confirmation No.: 9059

Filed: February 9, 2004

Art Unit: 1647

For: ANTI-TUMOR THERAPY TARGETING FLT4
(VEGFR-3) [AS AMENDED]

Examiner: Ian D. Dang

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

This paper is in response to the Office Action dated October 16, 2008 and is timely filed.

Please amend the above-identified U.S. patent application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 15 of this paper.